Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

In the Phase III MUSETTE study, a higher dose of intravenous Ocrevus (ocrelizumab) did not provide additional benefit in ...

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

One in three women will become pregnant after an MS diagnosis, therefore consideration of the maternal-infant dyad is needed.

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis The ...

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosisThe trial ...

The trial did not meet its primary endpoint; results support Ocrevus IV 600 mg as the optimal dose to slow disability progression - - High dose was well tolerated with an overall comparable safety ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion in adult patients with relapsing multiple ...

Swiss pharma major Roche (ROG: SIX) said a higher-dose version of its top-selling multiple sclerosis drug Ocrevus (ocrelizumab) failed to deliver additional benefit in slowing disability progression, ...

With its multiple sclerosis powerhouse Ocrevus expected to lose patent protection by the end of the decade, Roche is looking for ways to extend the market exclusivity for the top-selling drug in ...